Medindia

X

Oncology Physician Resource (OPR) Extends Agreement With OTN and Onmark as Oncology Services Partner

Tuesday, November 6, 2007 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., Nov. 5 OTN, a leadingphysician services company and one of the largest distributors of products andservices to the community physician market, and Onmark, a national grouppurchasing organization (GPO) for community-based practices, today announcedthat Oncology Physician Resource (OPR) has extended its existing partnershipwith OTN and Onmark for another year. Under the extended agreement, which isworth more than $200 million, OTN and Onmark will continue to provide OPRmembers with a wealth of oncology services, including drug distributionresources, technology and practice management solutions, clinical services,educational opportunities and GPO services.

OPR is a professional limited liability company owned by physician memberswho are dedicated to strengthening oncology practices through optimizingoperational efficiencies and maximizing purchasing power. OPR representsapproximately 100 oncologists in 42 practices at 77 sites located primarily inMichigan.

"We are continuing our successful partnership with OTN and Onmark becausewe are very pleased with their outstanding customer service, competitivepricing and commitment to innovation. We look forward to extending ourrelationship to continue to provide value to our OPR members," said PhilipStella, M.D., President and CEO of OPR.

OTN provides the broadest set of services, technology, pharmaceuticals,supportive care products and medical/surgical supplies to physicianspracticing in the community-treatment setting. Under the extended agreement,OPR's members will continue to have access to OTN's Lynx(R) oncology-specific,web-based technology platform, which includes Lynx Mobile(TM), Lynx EMR(TM),Lynx Station,(TM) Lynx Practice Manager(TM); and other practice managementtools, including Lynx Practice Intelligence(TM) Reports.

Through Onmark, OPR members will continue to have access to competitivecontracts for oncology drugs from 17 leading pharmaceutical manufacturers,exclusive discounts and practice optimization services, including OnmarkRegimen Profiler(TM), a web-based tool that helps practices and patientsunderstand financial and clinical information for commonly used oncologytreatment regimens. OPR practices can utilize Onmark's numerous education andsupport programs, as well as clinical webcasts and teleconferences, andclinical advisory boards.

"OPR's decision to continue its partnership with OTN is a testament to oursolid track record of delivering products, technology and services to supportthe most cost-effective and highest-quality care, and to preserve thecommunity-based treatment setting for oncology patients," said Gena Cook, VicePresident, Sales and Marketing, OTN. "OTN continues to be focused on providinga broad set of customized solutions to physicians who practice in thecommunity-based treatment setting. Customers like OPR recognize our dedicationto the physician community and the value OTN brings to their practices."

About OTN

OTN, a McKesson Specialty company, is a leading physician services companythat provides a broad set of customized solutions, including technology,pharmaceuticals, supportive care products and medical/surgical supplies, tophysicians who practice in the community-based treatment setting. Through itsinnovative Lynx(R) technology platform, practice management tools andunsurpassed customer service, OTN helps physicians remain independent andimprove practice efficiency while enabling them to focus on providing optimalpatient care. OTN's specialty pharmacy, provides physicians and their patientswith efficient delivery of medications to treat cancer, rheumatoid arthritis,infertility and other chronic conditions requiring the latest intravenous,injectable and oral medicines. OTN's affiliated group purchasing organization,Onmark, offers its members competitive contracts for oncology drugs andmedical/surgical s
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The HIV Vaccine Trials Network (HVTN) and Merck An...
S
Nventa presents HspE7 data at international HPV co...